Fosun Pharma has always been concerned by the industry with its excellent integration capabilities. Recently, its wholly-owned subsidiary, Fosun Industrial (Hong Kong) Co., Ltd., participated in the US-China mutual privatization transaction. Upon completion of the privatization transaction, Fosun Pharma will acquire a 30% stake in CML of US-China Mutual Benefits through its holding subsidiary for no more than US$45 million, which means that Fosun will become the controlling shareholder of the high-end medical chain brand and the family.
The transformation of pharmaceutical chain group, Fosun Pharma's privatization of US-China mutual benefit has been widely concerned by the market.
The current US-China mutual benefit business is mainly divided into two major parts. On the one hand, it is a medical health service, based on high-end medical care, and operates a “Hejia†hospital and clinic in China. It currently covers cities such as Beijing, Shanghai, Tianjin, Guangzhou and Wuxi to provide first-class high-quality international standard medical services. Features, which is the main department of obstetrics and gynecology brand.
According to the 2012 financial report released by US-China Mutual, the total assets of the US-China mutual benefit in 2012 was US$222 million, with operating income of US$152 million and net profit of US$4.09 million. According to the financial report for the first three quarters of 2013, from January to September 2013, US-China Mutual achieved operating income of US$130 million and net profit of US$4.01 million.
It is not difficult to see that the US-China mutual benefit has been losing money from January to September last year. A pharmaceutical industry analyst who did not want to be named said, "Because the hospital investment recovery cycle is relatively long, it is normal for the US-China mutual benefit to be in a loss state."
This transaction may not be cost-effective in terms of financial data. The reason why Fosun Pharma made this "losing business" is actually a picture. After privatization, Fosun Pharma can directly grasp the right to speak to the United States and China, and manipulate it to carry out future strategies in hospital layout.
At present, the “Heyijia†under the US-China Mutual Benefits has become the preferred brand of China's international high-end crowd medical care with the largest domestic network, the highest brand awareness and the highest degree of internationalization.
Strengthen medical device platform
It is understood that Fosun Pharma's medical diagnosis and medical device business revenue in 2012 was 1.06 billion yuan, of which medical diagnostics and medical device manufacturing business income was 590 million yuan, and medical device agency business income was 470 million yuan. At present, Fosun Pharma has a number of medical device companies including Changzheng Medicine, Fosun Pharma, Anji Chuangneng, Zhongsheng North Control, Fusheng Medicine and Fukun Medicine.
In April 2013, Fosun Pharma acquired the equity of Israel Felton Laser Co., Ltd. and cut into the high-end beauty medical device field, thus successfully completing the gorgeous turn from medical device agent to R&D and manufacturing.
prefried breaded PDTO shrimp
Pdto Shrimp,Breaded Pdto Shrimp,Prefried Breaded Shrimp,Prefried Breaded Pdto Shrimp
Zhoushan Junwei Aquatic Products Co., Ltd. , https://www.junweiaquatic-intl.com